Contract research organisation providing ion channel services to the drug discovery market.
Metrion Biosciences (Metrion) serve pharmaceutical and biotech clients to either perform cardiac screening services to understand if novel drug compounds have off-target effects or to develop new drug compounds that utilise ion channels.
Gresham House Ventures invested £2.25m as part of a £2.7m round. The investment will increase capacity, with enlarged lab facilities and specialist equipment; expand their service offering by adding a highly regulated GLP (Good Laboratory Practice) cardiac offering and expand their cell line library; and support further expansion in the United States. The investment continues our focus on outsourcing pharma services.
In December 2023, we topped up our investment by £1mn as part of a £3.7mn funding round.
Metrion has an experienced team providing a highly specialist service into a structurally growing market.
Investment rationale
Metrion has an experienced team providing a highly specialist service into a structurally growing market.
